What’s Propelling Immunogen Inc (NASDAQ:IMGN) After Lower Shorts Reported?

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Investors sentiment decreased to 1.21 in Q2 2019. Its down 0.08, from 1.29 in 2019Q1. It dropped, as 22 investors sold ImmunoGen, Inc. shares while 41 reduced holdings. 29 funds opened positions while 47 raised stakes. 100.23 million shares or 11.84% less from 113.69 million shares in 2019Q1 were reported.
Hrt Financial Lc invested 0.01% in ImmunoGen, Inc. (NASDAQ:IMGN). Janney Montgomery Scott Limited Liability Com accumulated 76,324 shares or 0% of the stock. Burt Wealth Advsr stated it has 500 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Blackrock reported 11.95M shares. Virtu Finance Llc accumulated 85,460 shares. Tekla Capital Lc holds 168,190 shares or 0.01% of its portfolio. Citadel Limited Liability invested in 0% or 1.01 million shares. Barclays Public Limited Company accumulated 338,892 shares or 0% of the stock. Birchview Capital Ltd Partnership stated it has 0.24% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Twin Focus Prtnrs Lc invested 0.1% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Amalgamated State Bank invested in 23,925 shares. Clear Harbor Asset Ltd Limited Liability Company holds 92,100 shares or 0.04% of its portfolio. Bartlett Llc accumulated 97 shares. Carroll Financial holds 155 shares.

The stock of Immunogen Inc (NASDAQ:IMGN) registered a decrease of 34.5% in short interest. IMGN’s total short interest was 7.13 million shares in September as published by FINRA. Its down 34.5% from 10.88 million shares, reported previously. With 3.65 million shares average volume, it will take short sellers 2 days to cover their IMGN’s short positions.

The stock decreased 0.62% or $0.02 during the last trading session, reaching $3.18. About 1.33M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 76.42% since September 13, 2018 and is downtrending. It has underperformed by 76.42% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $476.63 million. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: Seekingalpha.com which released: “ImmunoGen Q2 2019 Earnings Preview – Seeking Alpha” on August 01, 2019, also Seekingalpha.com with their article: “ImmunoGen Q1 2019 Earnings Preview – Seeking Alpha” published on May 02, 2019, Seekingalpha.com published: “ImmunoGen reboots operations after mirvetuximab soravtansine flop – Seeking Alpha” on June 27, 2019. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: Nasdaq.com and their article: “Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for – Nasdaq” published on April 26, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy Friday Option Activity: IMGN, SPWR, MMM – Nasdaq” with publication date: April 12, 2019.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.